Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial
Background: The Antibody Mediated Prevention (AMP) trial evaluated if VRC01, a CD4 binding site broadly neutralizing antibody, could prevent HIV-1 acquisition. To inform our understanding of how prevention efficacy depended on viral env gene charateristics, viral quasis-pecies and neutralization sen...
Gespeichert in:
| Veröffentlicht in: | Journal of the International AIDS Society 2021-01, Vol.24 (S1), p.10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | S1 |
| container_start_page | 10 |
| container_title | Journal of the International AIDS Society |
| container_volume | 24 |
| creator | Williamson, C Westfall, D Deng, W Pankow, A Matten, D Murrell, B York, T Nyangiwe, A. Gwashu Rolland, M Edlefsen, P Giorgi, E Magaret, C Montefiori, D Morris, L Cohen, M.S Corey, L Hural, J McElrath, J Juraska, M Gilbert, P.B Mullins, J.I |
| description | Background: The Antibody Mediated Prevention (AMP) trial evaluated if VRC01, a CD4 binding site broadly neutralizing antibody, could prevent HIV-1 acquisition. To inform our understanding of how prevention efficacy depended on viral env gene charateristics, viral quasis-pecies and neutralization sensitivity of HIV-1 breakthrough infections were analyzed. Methods: The trial evaluated VRC01 in women from sub-Saharan Africa (703/081); and men and transgender persons who have sex with men (704/085), from the Americas. Control samples from Thailand, Kenya and South Africa are being used for calibrating infection timing using sequence data. Rev-env-nef (REN) sequences were generated using Sanger and PacBio Single Molecule Real-Time (SMRT) sequencing platforms. To improve PacBio accuracy and enable quantitation, each viral RNA molecule was labelled with a unique molecular identifier (SMRT-UMI). Rev-env genes from imputed founder viruses were synthesized for pseudovirus production and in vitro sensitivity to VRC01 determined using the TZM-bl assay. Results: Approximately 84 000 unique REN sequences were generated from the first HIV-1 positive visit from 218 infected individuals in both trials, and two to four weeks later from a subset of individuals, providing a median of 174 unique env sequences per participant per time point. In approximately 2/3 of individuals, viral diversity was low, consistent with infection with a single founder virus. Of the 1/3 of individuals with higher viral diversity, consistent with infection with multiple founders, a third had low frequency variants ( |
| doi_str_mv | 10.1002/jia2.25659 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A656303505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A656303505</galeid><sourcerecordid>A656303505</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1365-fd2eeb08094a2b8452d1f9f6c887c7692ceca64e21c42993f8063c4c8f36f02b3</originalsourceid><addsrcrecordid>eNptz1FLwzAQB_AgCs7pi58gIPjWmaRNlj6WoW6gKKJ7HWl6aTO7RJJ0sG_vRB8mjHu44_j9Dw6ha0omlBB2t7aKTRgXvDxBIzrlMmOCs9OD-RxdxLgmRDBZlCOkKqf6XbQRe4NbcJCsxo3dQog27bByDV6-zQjFXwFiHAJg7_B8scworgOoz9QFP7Qd3towRIjYBL_BqQNcPb_iFKzqL9GZUX2Eq78-Rh8P9--zefb08riYVU9ZS3PBM9MwgJpIUhaK1bLgrKGmNEJLOdVTUTINWokCGNUFK8vcSCJyXWhpcmEIq_Mxuvm926oeVtYZn4LSGxv1qhJc5CTnhO9VdkT9PB5U7x0Yu1__85Mjfl8NbKw-Grg9CHSg-tRF3w_JehcP4TcCwYDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Williamson, C ; Westfall, D ; Deng, W ; Pankow, A ; Matten, D ; Murrell, B ; York, T ; Nyangiwe, A. Gwashu ; Rolland, M ; Edlefsen, P ; Giorgi, E ; Magaret, C ; Montefiori, D ; Morris, L ; Cohen, M.S ; Corey, L ; Hural, J ; McElrath, J ; Juraska, M ; Gilbert, P.B ; Mullins, J.I</creator><creatorcontrib>Williamson, C ; Westfall, D ; Deng, W ; Pankow, A ; Matten, D ; Murrell, B ; York, T ; Nyangiwe, A. Gwashu ; Rolland, M ; Edlefsen, P ; Giorgi, E ; Magaret, C ; Montefiori, D ; Morris, L ; Cohen, M.S ; Corey, L ; Hural, J ; McElrath, J ; Juraska, M ; Gilbert, P.B ; Mullins, J.I</creatorcontrib><description>Background: The Antibody Mediated Prevention (AMP) trial evaluated if VRC01, a CD4 binding site broadly neutralizing antibody, could prevent HIV-1 acquisition. To inform our understanding of how prevention efficacy depended on viral env gene charateristics, viral quasis-pecies and neutralization sensitivity of HIV-1 breakthrough infections were analyzed. Methods: The trial evaluated VRC01 in women from sub-Saharan Africa (703/081); and men and transgender persons who have sex with men (704/085), from the Americas. Control samples from Thailand, Kenya and South Africa are being used for calibrating infection timing using sequence data. Rev-env-nef (REN) sequences were generated using Sanger and PacBio Single Molecule Real-Time (SMRT) sequencing platforms. To improve PacBio accuracy and enable quantitation, each viral RNA molecule was labelled with a unique molecular identifier (SMRT-UMI). Rev-env genes from imputed founder viruses were synthesized for pseudovirus production and in vitro sensitivity to VRC01 determined using the TZM-bl assay. Results: Approximately 84 000 unique REN sequences were generated from the first HIV-1 positive visit from 218 infected individuals in both trials, and two to four weeks later from a subset of individuals, providing a median of 174 unique env sequences per participant per time point. In approximately 2/3 of individuals, viral diversity was low, consistent with infection with a single founder virus. Of the 1/3 of individuals with higher viral diversity, consistent with infection with multiple founders, a third had low frequency variants (<5% of sequences). We synthesized 1 to 4 Env-pseudoviruses per person, and identified some individuals infected with variants with different neutralization phenotype, including infection with both sensitive (IC.sub.80]<1 [micro]g/mL) and resistant ([IC.sub.80]>3 [micro]g/mL) viruses. In some individuals, the unique VRC01 resistance mutations were associated with distinct viral lineages, suggestive of infection with resistant viruses. However, we also found evidence of low frequency resistant mutations, that were likely derived from resistance acquired after infection. Conclusions: SMRT-UMI sequencing allowed a very detailed evaluation of viral populations following infection, including identification of minor founders not detected using conventional approaches. We found evidence of infection with viruses of mixed neutralization phenotypes, and in some cases, low frequency resistance mutations that were likely to be due VRC01 pressure. The study is not yet unblinded.</description><identifier>ISSN: 1758-2652</identifier><identifier>EISSN: 1758-2652</identifier><identifier>DOI: 10.1002/jia2.25659</identifier><language>eng</language><publisher>International AIDS Society</publisher><subject>AIDS (Disease) ; AIDS research ; Genetic aspects ; Health aspects ; HIV (Viruses) ; HIV infection ; Monoclonal antibodies ; Prevention ; Sexually transmitted diseases ; Testing</subject><ispartof>Journal of the International AIDS Society, 2021-01, Vol.24 (S1), p.10</ispartof><rights>COPYRIGHT 2021 International AIDS Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Williamson, C</creatorcontrib><creatorcontrib>Westfall, D</creatorcontrib><creatorcontrib>Deng, W</creatorcontrib><creatorcontrib>Pankow, A</creatorcontrib><creatorcontrib>Matten, D</creatorcontrib><creatorcontrib>Murrell, B</creatorcontrib><creatorcontrib>York, T</creatorcontrib><creatorcontrib>Nyangiwe, A. Gwashu</creatorcontrib><creatorcontrib>Rolland, M</creatorcontrib><creatorcontrib>Edlefsen, P</creatorcontrib><creatorcontrib>Giorgi, E</creatorcontrib><creatorcontrib>Magaret, C</creatorcontrib><creatorcontrib>Montefiori, D</creatorcontrib><creatorcontrib>Morris, L</creatorcontrib><creatorcontrib>Cohen, M.S</creatorcontrib><creatorcontrib>Corey, L</creatorcontrib><creatorcontrib>Hural, J</creatorcontrib><creatorcontrib>McElrath, J</creatorcontrib><creatorcontrib>Juraska, M</creatorcontrib><creatorcontrib>Gilbert, P.B</creatorcontrib><creatorcontrib>Mullins, J.I</creatorcontrib><title>Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial</title><title>Journal of the International AIDS Society</title><description>Background: The Antibody Mediated Prevention (AMP) trial evaluated if VRC01, a CD4 binding site broadly neutralizing antibody, could prevent HIV-1 acquisition. To inform our understanding of how prevention efficacy depended on viral env gene charateristics, viral quasis-pecies and neutralization sensitivity of HIV-1 breakthrough infections were analyzed. Methods: The trial evaluated VRC01 in women from sub-Saharan Africa (703/081); and men and transgender persons who have sex with men (704/085), from the Americas. Control samples from Thailand, Kenya and South Africa are being used for calibrating infection timing using sequence data. Rev-env-nef (REN) sequences were generated using Sanger and PacBio Single Molecule Real-Time (SMRT) sequencing platforms. To improve PacBio accuracy and enable quantitation, each viral RNA molecule was labelled with a unique molecular identifier (SMRT-UMI). Rev-env genes from imputed founder viruses were synthesized for pseudovirus production and in vitro sensitivity to VRC01 determined using the TZM-bl assay. Results: Approximately 84 000 unique REN sequences were generated from the first HIV-1 positive visit from 218 infected individuals in both trials, and two to four weeks later from a subset of individuals, providing a median of 174 unique env sequences per participant per time point. In approximately 2/3 of individuals, viral diversity was low, consistent with infection with a single founder virus. Of the 1/3 of individuals with higher viral diversity, consistent with infection with multiple founders, a third had low frequency variants (<5% of sequences). We synthesized 1 to 4 Env-pseudoviruses per person, and identified some individuals infected with variants with different neutralization phenotype, including infection with both sensitive (IC.sub.80]<1 [micro]g/mL) and resistant ([IC.sub.80]>3 [micro]g/mL) viruses. In some individuals, the unique VRC01 resistance mutations were associated with distinct viral lineages, suggestive of infection with resistant viruses. However, we also found evidence of low frequency resistant mutations, that were likely derived from resistance acquired after infection. Conclusions: SMRT-UMI sequencing allowed a very detailed evaluation of viral populations following infection, including identification of minor founders not detected using conventional approaches. We found evidence of infection with viruses of mixed neutralization phenotypes, and in some cases, low frequency resistance mutations that were likely to be due VRC01 pressure. The study is not yet unblinded.</description><subject>AIDS (Disease)</subject><subject>AIDS research</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>HIV (Viruses)</subject><subject>HIV infection</subject><subject>Monoclonal antibodies</subject><subject>Prevention</subject><subject>Sexually transmitted diseases</subject><subject>Testing</subject><issn>1758-2652</issn><issn>1758-2652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptz1FLwzAQB_AgCs7pi58gIPjWmaRNlj6WoW6gKKJ7HWl6aTO7RJJ0sG_vRB8mjHu44_j9Dw6ha0omlBB2t7aKTRgXvDxBIzrlMmOCs9OD-RxdxLgmRDBZlCOkKqf6XbQRe4NbcJCsxo3dQog27bByDV6-zQjFXwFiHAJg7_B8scworgOoz9QFP7Qd3towRIjYBL_BqQNcPb_iFKzqL9GZUX2Eq78-Rh8P9--zefb08riYVU9ZS3PBM9MwgJpIUhaK1bLgrKGmNEJLOdVTUTINWokCGNUFK8vcSCJyXWhpcmEIq_Mxuvm926oeVtYZn4LSGxv1qhJc5CTnhO9VdkT9PB5U7x0Yu1__85Mjfl8NbKw-Grg9CHSg-tRF3w_JehcP4TcCwYDg</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Williamson, C</creator><creator>Westfall, D</creator><creator>Deng, W</creator><creator>Pankow, A</creator><creator>Matten, D</creator><creator>Murrell, B</creator><creator>York, T</creator><creator>Nyangiwe, A. Gwashu</creator><creator>Rolland, M</creator><creator>Edlefsen, P</creator><creator>Giorgi, E</creator><creator>Magaret, C</creator><creator>Montefiori, D</creator><creator>Morris, L</creator><creator>Cohen, M.S</creator><creator>Corey, L</creator><creator>Hural, J</creator><creator>McElrath, J</creator><creator>Juraska, M</creator><creator>Gilbert, P.B</creator><creator>Mullins, J.I</creator><general>International AIDS Society</general><scope/></search><sort><creationdate>20210101</creationdate><title>Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial</title><author>Williamson, C ; Westfall, D ; Deng, W ; Pankow, A ; Matten, D ; Murrell, B ; York, T ; Nyangiwe, A. Gwashu ; Rolland, M ; Edlefsen, P ; Giorgi, E ; Magaret, C ; Montefiori, D ; Morris, L ; Cohen, M.S ; Corey, L ; Hural, J ; McElrath, J ; Juraska, M ; Gilbert, P.B ; Mullins, J.I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1365-fd2eeb08094a2b8452d1f9f6c887c7692ceca64e21c42993f8063c4c8f36f02b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>AIDS (Disease)</topic><topic>AIDS research</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>HIV (Viruses)</topic><topic>HIV infection</topic><topic>Monoclonal antibodies</topic><topic>Prevention</topic><topic>Sexually transmitted diseases</topic><topic>Testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williamson, C</creatorcontrib><creatorcontrib>Westfall, D</creatorcontrib><creatorcontrib>Deng, W</creatorcontrib><creatorcontrib>Pankow, A</creatorcontrib><creatorcontrib>Matten, D</creatorcontrib><creatorcontrib>Murrell, B</creatorcontrib><creatorcontrib>York, T</creatorcontrib><creatorcontrib>Nyangiwe, A. Gwashu</creatorcontrib><creatorcontrib>Rolland, M</creatorcontrib><creatorcontrib>Edlefsen, P</creatorcontrib><creatorcontrib>Giorgi, E</creatorcontrib><creatorcontrib>Magaret, C</creatorcontrib><creatorcontrib>Montefiori, D</creatorcontrib><creatorcontrib>Morris, L</creatorcontrib><creatorcontrib>Cohen, M.S</creatorcontrib><creatorcontrib>Corey, L</creatorcontrib><creatorcontrib>Hural, J</creatorcontrib><creatorcontrib>McElrath, J</creatorcontrib><creatorcontrib>Juraska, M</creatorcontrib><creatorcontrib>Gilbert, P.B</creatorcontrib><creatorcontrib>Mullins, J.I</creatorcontrib><jtitle>Journal of the International AIDS Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williamson, C</au><au>Westfall, D</au><au>Deng, W</au><au>Pankow, A</au><au>Matten, D</au><au>Murrell, B</au><au>York, T</au><au>Nyangiwe, A. Gwashu</au><au>Rolland, M</au><au>Edlefsen, P</au><au>Giorgi, E</au><au>Magaret, C</au><au>Montefiori, D</au><au>Morris, L</au><au>Cohen, M.S</au><au>Corey, L</au><au>Hural, J</au><au>McElrath, J</au><au>Juraska, M</au><au>Gilbert, P.B</au><au>Mullins, J.I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial</atitle><jtitle>Journal of the International AIDS Society</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>24</volume><issue>S1</issue><spage>10</spage><pages>10-</pages><issn>1758-2652</issn><eissn>1758-2652</eissn><abstract>Background: The Antibody Mediated Prevention (AMP) trial evaluated if VRC01, a CD4 binding site broadly neutralizing antibody, could prevent HIV-1 acquisition. To inform our understanding of how prevention efficacy depended on viral env gene charateristics, viral quasis-pecies and neutralization sensitivity of HIV-1 breakthrough infections were analyzed. Methods: The trial evaluated VRC01 in women from sub-Saharan Africa (703/081); and men and transgender persons who have sex with men (704/085), from the Americas. Control samples from Thailand, Kenya and South Africa are being used for calibrating infection timing using sequence data. Rev-env-nef (REN) sequences were generated using Sanger and PacBio Single Molecule Real-Time (SMRT) sequencing platforms. To improve PacBio accuracy and enable quantitation, each viral RNA molecule was labelled with a unique molecular identifier (SMRT-UMI). Rev-env genes from imputed founder viruses were synthesized for pseudovirus production and in vitro sensitivity to VRC01 determined using the TZM-bl assay. Results: Approximately 84 000 unique REN sequences were generated from the first HIV-1 positive visit from 218 infected individuals in both trials, and two to four weeks later from a subset of individuals, providing a median of 174 unique env sequences per participant per time point. In approximately 2/3 of individuals, viral diversity was low, consistent with infection with a single founder virus. Of the 1/3 of individuals with higher viral diversity, consistent with infection with multiple founders, a third had low frequency variants (<5% of sequences). We synthesized 1 to 4 Env-pseudoviruses per person, and identified some individuals infected with variants with different neutralization phenotype, including infection with both sensitive (IC.sub.80]<1 [micro]g/mL) and resistant ([IC.sub.80]>3 [micro]g/mL) viruses. In some individuals, the unique VRC01 resistance mutations were associated with distinct viral lineages, suggestive of infection with resistant viruses. However, we also found evidence of low frequency resistant mutations, that were likely derived from resistance acquired after infection. Conclusions: SMRT-UMI sequencing allowed a very detailed evaluation of viral populations following infection, including identification of minor founders not detected using conventional approaches. We found evidence of infection with viruses of mixed neutralization phenotypes, and in some cases, low frequency resistance mutations that were likely to be due VRC01 pressure. The study is not yet unblinded.</abstract><pub>International AIDS Society</pub><doi>10.1002/jia2.25659</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-2652 |
| ispartof | Journal of the International AIDS Society, 2021-01, Vol.24 (S1), p.10 |
| issn | 1758-2652 1758-2652 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A656303505 |
| source | DOAJ Directory of Open Access Journals; Access via Wiley Online Library; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | AIDS (Disease) AIDS research Genetic aspects Health aspects HIV (Viruses) HIV infection Monoclonal antibodies Prevention Sexually transmitted diseases Testing |
| title | Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A11%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20genetic%20diversity%20and%20VRC01%20pressure%20on%20HIV-1%20breakthrough%20viruses%20from%20the%20AMP%20trial&rft.jtitle=Journal%20of%20the%20International%20AIDS%20Society&rft.au=Williamson,%20C&rft.date=2021-01-01&rft.volume=24&rft.issue=S1&rft.spage=10&rft.pages=10-&rft.issn=1758-2652&rft.eissn=1758-2652&rft_id=info:doi/10.1002/jia2.25659&rft_dat=%3Cgale%3EA656303505%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A656303505&rfr_iscdi=true |